It. peripheral model for tlJe central 5-HT
WllerL'Us baseline to elllipoint denSity (8 ..... ,) clla"g~'S (6 ) were similar for IMI (183 ± 329 fmollmg) alld FLU (196 ± 402/",011"'g) 47-53, 1996/ one neurotransmitter in the modulatio n of mood stales remains obscure, a signilicant role for the indoleamine serotonin (5-HT) is likely (vanPraag 1986; Baldessarin i 1983) . However, the systematiC study of central amines. s uch as 5-HT, across large mood-disordered populations is problematic . As an alternative, the utility of peripheral markers has been s uggested (Sneddo n 1973; Stahl 1977 ), O ne s uch marker is the imipramine (IMI) binding site on platelet Langer et al. 1984) .
Since the description of the lMI-binding site ove~ 15 years ago, evidence for its functional relevance has accumulated . As part o f a macromolecular complex, IMI and related ligand-binding sites are under allosteric modulatio n by 5-HT; a biphasic 0893-133XI96I$15_00 550J OH'J3-133X(95)00076--P effect o n the disassociation rate for the IMI-sile has been d escribed (O 'Riordan et al. 1990) . Evidence s uggests that a strong correlation exists between brain and platelet PHHMI binding prol1les (Paul et al. 1981; Rehavi et al. 1983 ). Evidence for s ite specificity includes observatio ns that I' HI-IMI binding can be inhibited by 5-HT uptake inhibitors in relation to their potency Paul et al. 1981) .
The characterization of P HI -IMI binding s ites o n human blood platelets has led to a proposed functional relatio ns hip to d e pression (Paul et al. 1981; Rais man et al. 1982; Suranyi-Cadotte 1980; Raisman et al. 1981) . Decreased P HI-IMI binding, principally receptor density ( Bm.o~) , has hccn reported in both human brain and platelet preparations from unmedicated depressed patients (Nemeroff et al. 1988) .
In this trial. the hypothetical relationship of I' H)-IM! binding (platelet) and clinical response to antide pressant pharmacotherapy was assessed . We evaluated 33 s ubjects with a Diag nostic and Statistical Manual of Mental Disorders. 3rd edition-revised (DSM-III -R) (America n Psychiatric Association 1987) majorde prcss ion and Research Diagnostic Criteria (ROC) (Spitzer et al. 1977 ) compatible agitation w ho had been rand omized to either flu oxetine (20 to 60 mg) or imipramine (50 to 300 mg) for 6 weeks as part o f a larger d ouble-blind trial. Platelet P H)-IMI binding prol1les were analyzed relative to a numher o f cl inical questio ns including response predictio n, between-drug d iffe re nces, and s tate-associated phenomena .
METHODS
This was a do uble-blind , rando mized parallel s tudy. The trial was divided into two periods: a 1-week (6-to 10-day), single-blind. placebo lead -in (stud y period 1) and an 8-week, d ouble-blind, randomized treat ment period (study period 2). Visits were scheduled at1-week (6-to 10-day) intervals. Subjects who met e ntry screening criteria and did not exhibit a 25% or greater reductio n from their Hamilto n Depressio n Rating Scale-17 ite m (HAM D) (Hamilto n 1960) screening value during s tudy period 1 were randomly assigned at baseline to receive either fluoxetine (FLU) 20 mg/day or imipramine (IMI) 150 mg/day (the latter titrated over a 2-wcck period). Dose escalation beyond the initial fi xed targets was permitted after week 4 o f do uble-blind thera py at the inves tigato r's discretion . This s tudy was part of a larger two-site trial (n -80) previous ly reported (follefson et al. 19(4) ; however, the ('H)-1M I assays were collected at o nly o ne s ite as a s tudy addendum (n -33) .
In order to be eligible for screening into the trial, candidates aged 18 to 65 years were required to meet major depression (unipolar) diag nostic criteria according to the DSM-III -R (APA 1987) and the agitated s ub-I EUIlO r5YC II OrIlA RMACO LOG Y 199f.-VOL . 14, NO. 1 type per ROC (Spitzer et al. 1977) . Subjects were also required to score a minimum of 16 o n the HAMD I 7. Principal exclusionary criteria included serious concom· itant medical illness, recent usc o r coprescription of any centrally active med icatio ns, and other DSM-III-R axis-l comorbidity .
PLATELET PREPARATION Platelets fo r the binding studies were obta ined using a mod ification of the methods of Briley et al. ("1979 Briley et al. (" , 1980 and As. 1rch et .11. (1980) . Using evacuated glass tubes contai ning 2 ml of acid citrate-d extrose solution as an anticoagulant , 35 ml of w hole blood was withdrawn from the antecubital vein . Platelet-rich plas ma wasobtained by centrifugation at 100 g for 30 minu tes. The platelet-rich plas ma was then centrifuged (l6,()()() g for 10 minutes at 4°C) and the resulting platelet-rich pellet was s uspe nded in 50 mmol ofTR IS buffer (pH , 7.5 lit 4°C) co ntaining 15 mmol of sod ium chloride and 20 mmol of EDTA acid us ing Po lytro n homogenization (Polytron , Brinkmann Ins truments, Wes tbury, Y) medium probe at setting of 4 for 10 to 15 seconds. After centrifugatio n at 39,000 g for 10 minutes, membranes were p repared by hypoto nic lysis in 5 mmol TRIS (pH. 7.5). containing 5 mmol EDT A and the n homogenized and ce ntrifuged at 39,<XXJ g fo r 10 minutes.
Th e s upernatant was discarded and the pellet was washed by res us pens ion in 70 mmolfL TRI S (pH, 7.5), and centrifuged agai n at 39,()()() g for 10 minutes. The was hed pellet was fin ally resu s pended in the assay buffer, w h ich consisted of .50 mmol/L TRIS (pH 7.5 al 4°C) con taining 120 mmolfL of sodium chloride and 5 mmoll L of potassium chloride . Aliquots were taken for protein determinatio n according to the method of Low ry et al. (1951) and the remainder frozen at _70°C until used in the binding assay . No differences in P H)-IMl binding properties between frozen and unfrozen platelet pre parations have previous ly been secn.
BIND INC ASSAY
Pl atelet p HI-imipramine binding was dete rmined using a modification of the procedu re of Rais man et al. (1981; . In each sample, total binding was assayed at seven diffe rent concentration s (0.25 nmoll l to 8 nmolll ) of tritiated p lil-imipramine (spedfJ.c act ivity, 45 .4 C i/ mmol); the KI) was approximately 1 nmol. Each assay tube (all concentrations were meas ured in triplicate) contained approximately 100 Ilg o f platelet protein, and the I1nal assay volume was 250 Ill. Tubes were incubated with the radiolabel fo r 60 minutes on ice . The reactio n was s topped by additio n o f 5 ml of ice-cold assay buffer, and bound radioactivity was col-lecled by fLltration under vacuum over glass fiber filters presoaked for 3 hours in buffer. The filters were then washed three times w ith 5 ml of ice-cold assay buffer. Nonspecific binding was defined as binding persisting in the presence of 100 110101 of desipramine . Specific binding of [l H ]-imipramine to platelet membranes was calculated as the difference between total binding minus nonspecific binding. Specifi c binding represented 80% of total binding, which was less than 5% o f the total counts added. Scatchard analysis was used to obtain the B"",~ a nd Ko for tritia ted imipramine (Scatchan:! 1949). Linear regression of Scatchard plots was used 10 determine the correlation coefficient r. Assays with rles.s than 0.90 were excluded. The interassay coefficient of variation for this method is approximately 10% for BlIW~ and 5% for KI). Institute Inc. 1990 ) proced ures were used to perform all s ta tis tica l analyses. Comparisons between treatment gro ups at baseline, for demographiccharacteristics, were made us ing either a 2 x 2 Pearson 12 test or a Wilcoxon rank sum test. Patient disposition, in terms of the reasons for discontinuation from the study, ..... ere analyzed using 2 x 2 Pearson 12 tests. Baseline and cha nges from baseline to endpoint for all clinical measures (HAMDI7, HAMA , ASIQ, ARS) were compared between treatment groups using a o ne-way ANOVA on rank transformed data . For KD and Bm;n, within·treatment group compa risons were performed using the paired Wilcoxon s ig ne d rank test a nd betv.'een-treatme nt comparisons used a o ne-way ANOVA on rank transformed data.
STATISTICAL PROCEDURES SAS (SAS
Correlatio ns between platelet and clinical measures were made us ing Spearman's rank-orde r correlation coefficient. Correlatio n coefficients within each treatment group, and for both treatments combined, were calculated.
RESULTS
A total of 33 subjects provided baseline and endpoint samples for the platelet PH ]-IMI binding assay . individual baseline demographic fealwes are summarized in Table 1 Table 2 .
Baseline to last vis it (all s ubjects with at least one postrandomized visit) change scores across the primary efficacy measures are s ummarized in Table 3 . While s tatis tically s ig nillcan t in its superior anxiolytic profiJe, FLU was numerically favored o n three of the four clinical assessments. Table 4 (p < .05) . However, no signiftcant between-treatm ent differences were detected. Within group comparisons using a Wilcoxon-signed rank analysis indicated a poss ible nonspecific treatment effect on PHJ-IMI receptor dens ity (Bmax). In both treatment groups, Bm~x median and mean values increased during the trial (see Table  4 ). However, there was nostatis tically Significant difference between treatment groups (p _ .65) nor relationship to clinical outcom e. In contrast, a statistically signifIcant increase in receptor afftnity (Ko) at e ndpoint characterized the FLU (p _ .024) but not the IMI study arm . With in both treatment groups pooled endpoint KI) values correlated signiftcantly with treatment-asso- dated '-lAMA change (r --0.38; P -.02) and trended with ARS change (r --0.31; P -.06); however. no differences emerged between the two therapies. In the analysis of baseline to endpoint change (a) betweengroup difference in aKo was highly signihcant (p _ ,(X)4). aKo was in a positive direction for FLU a nd conversely, negative for IMI . Of further interest, a correlational trend between 6.Ko and 6.HAMD I7 emerged in the FLU arm {r -0.41; p -.(m but not the IMI arm (r -0.07; P -.81).
DlSCUSS10N
In this compa rative trial in major depression with agitation, both FLU and IMI d emonstrated comparable efficacy (see Table 3 ). This was consistent w ith p revious comparisons reviewed by 8enheld and associates (1986). However, the s uccess of phannacotherapy rests on a ravorable risk: beneht ratio . In this cohort, IMI was s ignificantly less well tolerated than FLU-i.e., mort IMI patients discontinued their antidepressant befoft the e nd or the eighth treatment week because of Ont or more adverse events.
Platelet and neuron share a number of common em.
bryologic features . Platelets, like the human neuron, exhibit an amine-precursor-uptake decardboxylatioo system (Pearse 1986 ~.
O~----~FL~X----~~~l----~ Figure 1 . Display of baseline Ko and responder status al endpoint. Signilicance: no significant difference between treatments (p _ .695), significant difference between responders and non-responders (p -. (46), and no significant treatment response interaction (p -.615). Legend: 6. non.responders, o responders, "' " median Kn for non-responders, -median Ko for responders.
Affmity
ObservatiOll1. In the present study 1 3 HI-IMI binding proftles were correlated with a series of clinical outcome measures. A key observation was thai a higher base· line receptor affinity for PHI · IMI was related to a greater level of clinical improvement. This relationship held true for subjects assigned to either IMI or FLU. One interpretation could be that pharmacologic reo sponse (at least to the two antidepressants examined in this study) is likely tooccuronly when a certain level of baseline affinity is present . If this minimal threshold is not present, the dynamic capacity of the transport apparatus may be incapable of mediating drug reo sponse. In s uch cases the conventional uptake inhibi· tors may prove less than optimal in achieving symptomatic improvement.
Observation 2. In this trial was a positive trend between 6.Ko and 6.HAMD among s ubjects randomized 10 FLU (p -.09) emerged . In contrast, no such rela· tionship occurred among IMI subjects. The latter observat ion is consistent with previous ftndings reported for both desipramine and imipramine. A possible understandingof this difference is that although both an· tidepressants block S-I-IT uptake, they may bind at two related but different sites within the uptake complex (Ahtee et al. "1981 ; Raisman ct al. 1982; O'Riordan et al . 1990 ). The PHj·IM I binding sile and the S·HT rec· ognition site are linked via a sodium·dependent mech· anism (Abott et 011. 1982) . In contrast to 1M!. changes in PHI-IMI binding induced by SSRls such as FLU are indirect and med-iated via the S·HT recognition site lH-IM I Binding and Depression Response Sl (Wen nogle and Meyerson 1983) . Thus, the divergent results between the two treatments seen in the p resent study suggest FLUs bi nding directly at the5-HT trans· porter may have better reflected the dynamic process associated with a positive treatment outcome. How· ever, the observation that both FLU and IMI had comparable overall efficacy illustrates that modihcation of 5·HT transporter affinity is not mandatory for clinical improvement. Obviously the additional effects of IMI and its desmethylated metabolite on noradrenergic sys· terns Cannot be dismissed . It is further possible that the conflrmational state of the 5·HT substrate recognition site could be sensitized through the presence of an endogenous competitive S-HT antagonist. Barkai and colleagues reported that increasing amounts of a membrane·derived protein that competitively inhibited PHI-IMI binding (Ko but not Bma~). Paul et al. (1980) also observed that the addition of plasma to a cortical membrane preparation Significantly inhibited binding. Such fmdings suggest the existence of an endogenolls inhibitor in platelet preparations capable cr mediating a concentration-dependent effect on transporter' site affinity. Furthermore, this could explain the apparent predictive threshold of baseline Ko reported in this present study. Furthermore, if the inhibitor were competitive, a greater treatment-associated change might be expected with a competitive 5·HT uptake inhibitor such as FLU than a noncompetitive one (imipramine) .
Observatioll 3. Baseline and endpoint [JH[ ·IMI KD were rela ted to both HAMA and ARS scores. However, there was no apparent relationship between the magnitudes of baseline to endpoint change. Thus, any sug· gestion that features of anxiety or agitation are reflected at the transporter is tenuous. However, previously suggested relationships between the5·HT system and ad· verse drug experiences such as anxiety, hostility, rest· lessness, etc., make the possible link intriguing and worthy of future investigation .
Density
Baseline Bmu val ues in the present study are difficult to interpret in the absence of a control group. The mean study population valueofl665 fmolfng was somewhat lower than previously reported among matched controls as conducted by the same laboratory (Nemeroff et al. 1988) . Briley et al . (1980) reported that depressed subjects demonstrate reduced PHI·IM I binding den· sity. Although conftrmed by others, this observation has not been universal Significant variability in PHI-IMI assay methods and an apparent overlap in the distribution of depressed and control subject values renders any conclusions difficult . Other reported variables were controlled for in the present study including subject's age, time of blood draw, seasonality. and confounding drug treatments. RegardJess, some degree of reduced PHI-IMI SINK among major depressives is defensible (Nemeroff et al. 1988) . This is particularly true in view o f the recent meta-analysis of platelet (3HI-IMI binding, which revealed a highly signilicant reduction in depressed pa tients . Of interest Urn ... was altered after pharmacotherapy. The density of PHI-1M I binding sites demonstrated an increase from baseline to endpoint in both treatment arms. This was congruent with the conclusion of Hea ly and colleagues (1991) that "an increase in PHI-1M! binding may be common to all antidepressant treatments ." The observed direction of change was consistent with that reported after TCA exposure by other inves tigators (Braddock et al. 1984 ; Arora and Meltzer 1988; Wagner et al. "1987) . However, in the present study. change in Sm.u was not signilicantly related to any of the clinical o utcome measures used . More likely a change in Bm .... during treatment of either depressives or normal controls, as noted by Healy et al. (1991 ) . is independent of a spedlic reduction in depressive signs and/or symptoms.
CONCLUS IONS
Among ROC compatible major depressives with baseline agitation, IMI and FLU were similarly effective. Of note, FLU was better tolerated as reflected by significantly fewer premature treatment discontin uations due to an adverse event. Becau se the mod e of action among differing antidepressant drugs may shed light on the associated biology o f the affective disorders, the platelet findings reported here are of potential interest .
Analyses involving the platelet 5-HT transporter revealed that baseline Ko correlated with endpoint score reductions in depression, anxiety, agitation , and s uicidality. This observation was independent of s tudy drug randomization . These results suggested that a certain conformation s tateof the S-HT transporter complex may predict or be required for a positive treatment outcome. Future resea rch efforts might be directed toward the identification of o ne or mo re competitive e ndogenous antagonists at the transporter.
A second observation was that only FLU-treated subjects demonstrated an interrelationship between baseline to endpoint changes in P HI-IMI binding afflOit y and HAM011. Mo reover, the direction of treatment-associated Ko change was op posite for FLU versus 1M!. Whereas the magnitude of Ko change could be questio ned for its biologiC significa nce, the statistically sig nifica nt relationship to several clinical outcome measures argues for its relevance. Future testing of the hypothesis that the scope of antidepressant response (I-lAMD11) may be reflected by a modifica tion of the 5-HT transporter's affinity with selective NEU ItOPSYCllO rH ARMACOI.OCV 1996-VOI.. 14, NO.1 agents, e.g., fluoxetine , is encouraged. The dati reported here p rovide for a prediction of the sa m pl~ size ne('essary to minimize the risk of type 11 errors in future s tudies. Bmn, a mo re frequent subject for comparison between depressed subjects and controls, was associated with a nonspecilic treatment-related in· crease. The direction of change was consistent with sev· eral previous reports among both normal controls and depressed subjects. Because the observed increase was not SignifIcantly related to any of the treatment outcome meas ures, its clinical relevance is questionable.
The observations from this study (as with previ· ous literature) sho uld be tempered by methodologic variance between laboratories, possible selection bias among subjects participating in controlled clinical trials, interindividual variability of PHI-1M I binding paramo eters, platelet heterogeneity, etc. However, this sample was rigorously diagnosed, assessed, and monitored for compliance. Efforts were in place to minimize in· trasubject variables. The methods for the PHI-IMI assay have been previously vaJidated and were conducted by an experienced group.
In view of the findings, larger sample sizes using similar methodology are encouraged to validate the 00. served results. If platelet P HI-1M I binding affinity, Of perhaps more specifically binding at the transporter, reflects corresponding changes within the neuronal 5-HT complex, then such studies present an o pportu· nity to explore and better understand the phenomenon of treatment response and therapeutic resistance.
